Precision medicine is evolving into a clinical standard, moving away from the “one-size-fits-all” drug development approach. By 2026, therapies are increasingly tailored for genetically defined subsets and biomarker-selected populations, making biomarker testing and central laboratory services crucial in clinical trials. Reliable biomarker data is essential for accurately identifying suitable patients and measuring biological responses, highlighting its role in the success of drug candidates in the precision medicine landscape.

Biomarkers are measurable indicators that reflect normal biological, pathogenic, or pharmacological processes, playing a transformative role in drug development by serving various critical functions.

In oncology, more than 70% of new molecular entities in clinical development now incorporate companion diagnostics, with similar biomarker-driven trials increasing in neurology, immunology, cardiology, and rare diseases. The increasing complexity of biomarker testing has surpassed the capabilities of local laboratories, making central laboratories essential.

  • Why Central Labs Are Critical for Biomarker-Driven Trials

Decentralized, site-specific biomarker testing leads to significant variability due to differences in equipment, reagents, reference ranges, and interpretation criteria among labs. This inconsistency can result in patient eligibility discrepancies across sites for criteria like PD-L1 expression, creating trial population heterogeneity that complicates the assessment of treatment effects and threatens regulatory approval.

Central laboratories solve this problem by providing:

  • Key Biomarker Testing Modalities in 2026

Central laboratories today offer a wide array of biomarker testing capabilities:

  • Immunohistochemistry (IHC) is used to assess protein expression, including markers like PD-L1, HER2, and hormone receptors. The process necessitates validated antibodies, scoring algorithms, and integration with digital pathology.
  • In situ hybridization (ISH/FISH) is a technique used for gene amplification, such as HER2, ALK, and ROS1. It provides either quantitative or qualitative results but necessitates specialized interpretation.
  • Next-Generation Sequencing (NGS) provides comprehensive genomic profiling, assessing tumor mutation burden and microsatellite instability. It is characterized by high complexity and necessitates advanced bioinformatics support, with a critical emphasis on turnaround time.
  • PCR and RT-PCR offer single or multi-gene mutation panels and gene expression signatures, providing a faster alternative to NGS when detecting well-defined hot-spot mutations.
  • Flow Cytometry is utilized for immunophenotyping in hematologic malignancies and minimal residual disease (MRD). It requires fresh or specially processed samples, with real-time analysis often necessary.
  • Liquid biopsy using circulating tumor DNA (ctDNA) enables non-invasive genotyping, monitoring treatment responses, and detecting resistance mutations. However, it faces challenges in identifying low-abundance mutations and necessitates the use of highly sensitive assays.
  • ELISA and MSD are immunoassay techniques utilized for measuring cytokines, soluble biomarkers, and pharmacodynamic markers. The use of multiplexing in these assays is becoming more prevalent, necessitating the validation of antibody pairs.
  • LC-MS/MS is a technique used for analyzing small molecule metabolites and proteomics panels, noted for its high specificity and the intensive method development it requires.

Common Pitfalls in Biomarker Testing and How Central Labs Avoid Them

Even with a central lab, biomarker testing can go wrong. Here are the most frequent failure modes:

  1. Inappropriate Sample Collection

Biomarkers rely heavily on the quality of their sample sources, such as whether plasma, serum, or whole blood is used, as well as the type of collection tube, processing time, and temperature. To maintain sample integrity, central labs offer comprehensive collection manuals, site training, and validated stability data.

  1. Assay Validation Gaps

Regulators mandate that biomarker assays must be validated in accordance with ICH M10 or CLSI guidelines, with central labs having specialized teams for method development and validation to provide necessary data for regulatory submissions.

  1. Delayed Turnaround Times

Biomarker-driven trials face recruitment bottlenecks due to delays in central lab eligibility results. However, leading central labs have improved turnaround times, offering rapid results (48–72 hours for IHC and 5–7 days for NGS) with data released 24/7.

  1. Sample Tracking Failures

Lost or misidentified samples pose compliance challenges. Modern central labs utilize barcode or RFID-based chain-of-custody tracking, frequently integrated with site portals for real-time sample status visibility.

  1. Lack of Contingency for Unstable Biomarkers

Biomarkers such as circulating RNA, phosphoproteins, and live cells can degrade quickly. Central labs offer verified protocols for sample stabilization, including specialized collection tubes and immediate cold-chain shipping, and may conduct on-site analysis at regional lab hubs.

  • The Global Central Lab Landscape in 2026

The central laboratory market is experiencing consolidation and globalization, with major players establishing networks across North America, Europe, Asia-Pacific, and Latin America. These networks facilitate logistical hubs that enhance shipping efficiencies and sample stability. In global precision medicine trials, having a central lab with regional processing centers is becoming the standard instead of relying on a single global location.

  • Key capabilities to look for in a 2026 central lab partner:

Regional labs offer a global footprint with expertise in time-sensitive assays while adhering to international regulatory certifications such as CAP, CLIA, ISO 15189, and OECD GLP, alongside country-specific accreditations. Digital integration is facilitated through APIs and secure portals for real-time data transfer to various clinical systems. The experience in companion diagnostic (CDx) development positions central labs to handle precision medicine trials effectively, from research to commercialization. Additionally, long-term sample storage supports biobanking for retrospective biomarker discovery and post-hoc analyses.

CurexBio offers assistance in  central laboratory and biomarker testing services integral to full-service clinical development. They collaborate with sponsors to create, validate, and implement biomarker strategies that enhance precision medicine trials from initial human testing to registration.

We offer scientific expertise and operational infrastructure for delivering reliable, inspection-ready biomarker data for targeted oncology therapies, gene therapies with pharmacodynamic biomarkers, and immunology drugs requiring patient stratification.

Ready to Power Your Next Precision Medicine Trial? Contact CurexBio today to discuss your biomarker strategy and central laboratory needs.